Shimadzu’s LCMS-8060 is designed to push the limits of LC/MS/MS quantitation for applications requiring the highest sensitivity and robustness while delivering a meaningful solution for routine LC/MS/MS analyses. It detects substances at ultra-trace level as they occur in complex matrices, for example, or in smallest sample concentrations which have to be diluted in order to avoid matrix effects.
A real difference to working better and faster
The LCMS-8060 is a member of Shimadzu’s UFMS (Ultra-Fast Mass Spectrometry) family and part of the Shimadzu mass spectrometry platform of MS/MS systems with ultra-fast technologies. It underlines Shimadzu’s role as one of the world’s fastest-growing mass spectrometry companies. The system combines a heated ESI source with all UF technologies including UFsweeper III, a collision cell filled with argon gas. Through its high speed technology, UFsweeper III achieves dwell times of 0.8 ms per MRM. With new UF Qarray ion guide technology increasing ion production and signal intensity, the LCMS-8060 introduces a new level of sensitivity and makes a real difference to working better and faster.
Highest sensitivity, fastest speed, outstanding durability
With a data acquisition scan speed of 30,000 u/sec and a polarity switching time of 5 msec the LCMS-8060 brings new levels of data quality and confidence at the highest sensitivity.
For more information please visit www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.